Chardan Capital reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR - Free Report) in a research note published on Tuesday morning,Benzinga reports. Chardan Capital currently has a $60.00 target price on the biotechnology company's stock. Chardan Capital also issued estimates for Arrowhead Pharmaceuticals' FY2025 earnings at ($1.27) EPS and FY2026 earnings at ($3.44) EPS.
Other research analysts have also issued reports about the company. HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Royal Bank of Canada reissued an "outperform" rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, B. Riley restated a "buy" rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $42.13.
Get Our Latest Research Report on Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Trading Up 2.4%
Shares of NASDAQ ARWR traded up $0.37 during mid-day trading on Tuesday, hitting $15.71. The company's stock had a trading volume of 1,821,408 shares, compared to its average volume of 1,483,733. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $30.41. The company's fifty day simple moving average is $13.30 and its 200-day simple moving average is $17.79. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of -3.04 and a beta of 0.89.
Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $2.81. The business had revenue of $542.71 million during the quarter, compared to analyst estimates of $116.27 million. During the same quarter in the prior year, the company earned ($1.02) earnings per share. On average, sell-side analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.
Insider Buying and Selling at Arrowhead Pharmaceuticals
In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total value of $2,269,327.66. Following the transaction, the chief executive officer now owns 3,773,802 shares of the company's stock, valued at approximately $64,230,110.04. The trade was a 3.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders sold 275,880 shares of company stock valued at $4,034,037. Company insiders own 4.30% of the company's stock.
Institutional Investors Weigh In On Arrowhead Pharmaceuticals
Large investors have recently made changes to their positions in the stock. Pacer Advisors Inc. boosted its stake in Arrowhead Pharmaceuticals by 11.6% in the 4th quarter. Pacer Advisors Inc. now owns 27,918 shares of the biotechnology company's stock worth $525,000 after purchasing an additional 2,907 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at about $651,000. Empowered Funds LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $268,000. KLP Kapitalforvaltning AS bought a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $434,000. Finally, Norges Bank bought a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $38,622,000. Institutional investors own 62.61% of the company's stock.
About Arrowhead Pharmaceuticals
(
Get Free Report)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Further Reading
Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.
While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
